505 related articles for article (PubMed ID: 26280447)
61. Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction.
Yenerçağ M; Arslan U; Dereli S; Çoksevim M; Doğduş M; Kaya A
Int J Cardiovasc Imaging; 2021 Jan; 37(1):165-173. PubMed ID: 32815051
[TBL] [Abstract][Full Text] [Related]
62. LCZ696, Angiotensin II Receptor-Neprilysin Inhibitor, Ameliorates High-Salt-Induced Hypertension and Cardiovascular Injury More Than Valsartan Alone.
Kusaka H; Sueta D; Koibuchi N; Hasegawa Y; Nakagawa T; Lin B; Ogawa H; Kim-Mitsuyama S
Am J Hypertens; 2015 Dec; 28(12):1409-17. PubMed ID: 25762811
[TBL] [Abstract][Full Text] [Related]
63. Role of Angiotensin Receptor-Neprilysin Inhibition in Heart Failure.
Prenner SB; Shah SJ; Yancy CW
Curr Atheroscler Rep; 2016 Aug; 18(8):48. PubMed ID: 27324636
[TBL] [Abstract][Full Text] [Related]
64. Safety and Tolerability of Initiating Maximum-Dose Sacubitril-Valsartan in Patients on Target Dose Renin-Angiotensin System Inhibitors.
Norberg H; Bergdahl E; Lindmark K
Cardiovasc Ther; 2019; 2019():6745074. PubMed ID: 31772613
[TBL] [Abstract][Full Text] [Related]
65. Evolution of functional class, biochemical and echocardiographic parameters and clinical outcomes after sacubitril/valsartan initiation in daily practice.
Morillas-Climent H; Seller-Moya J; Vicedo-López Á; Galcerá-Jornet E; Alania-Torres E; Rodríguez-Pichardo Y; Larumbe-Rodríguez A; Valle-Muñoz A
J Comp Eff Res; 2019 Jul; 8(9):685-697. PubMed ID: 31290687
[No Abstract] [Full Text] [Related]
66. Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF.
Balmforth C; Simpson J; Shen L; Jhund PS; Lefkowitz M; Rizkala AR; Rouleau JL; Shi V; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
JACC Heart Fail; 2019 Jun; 7(6):457-465. PubMed ID: 31078482
[TBL] [Abstract][Full Text] [Related]
67. Angioedema in heart failure patients treated with sacubitril/valsartan (LCZ696) or enalapril in the PARADIGM-HF study.
Shi V; Senni M; Streefkerk H; Modgill V; Zhou W; Kaplan A
Int J Cardiol; 2018 Aug; 264():118-123. PubMed ID: 29776559
[TBL] [Abstract][Full Text] [Related]
68. Sacubitril/valsartan: An important piece in the therapeutic puzzle of heart failure.
Marques da Silva P; Aguiar C
Rev Port Cardiol; 2017 Sep; 36(9):655-668. PubMed ID: 28844335
[TBL] [Abstract][Full Text] [Related]
69. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial.
Desai AS; Vardeny O; Claggett B; McMurray JJ; Packer M; Swedberg K; Rouleau JL; Zile MR; Lefkowitz M; Shi V; Solomon SD
JAMA Cardiol; 2017 Jan; 2(1):79-85. PubMed ID: 27842179
[TBL] [Abstract][Full Text] [Related]
70. [Neprilysin inhibition and chronic kidney disease].
Di Lullo L; Ronco C; Bellasi A; Cozzolino M; Floccari F; Barbera V; Verdesca S; Rivera R; De Pascalis A; Mudoni A; Santoro A
G Ital Nefrol; 2017 Sep; 34(5):102-112. PubMed ID: 28963831
[TBL] [Abstract][Full Text] [Related]
71. Angiotensin II Receptor-Neprilysin Inhibitor Sacubitril/Valsartan Improves Endothelial Dysfunction in Spontaneously Hypertensive Rats.
Seki T; Goto K; Kansui Y; Ohtsubo T; Matsumura K; Kitazono T
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29042424
[TBL] [Abstract][Full Text] [Related]
72. Evaluation of Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Sacubitril/Valsartan (LCZ696) and Sildenafil in Patients With Mild-to-Moderate Hypertension.
Hsiao HL; Langenickel TH; Petruck J; Kode K; Ayalasomayajula S; Schuehly U; Greeley M; Pal P; Zhou W; Prescott MF; Sunkara G; Rajman I
Clin Pharmacol Ther; 2018 Mar; 103(3):468-476. PubMed ID: 28599060
[TBL] [Abstract][Full Text] [Related]
73. Neprilysin Inhibitors in Cardiovascular Disease.
Kang G; Banerjee D
Curr Cardiol Rep; 2017 Feb; 19(2):16. PubMed ID: 28185171
[TBL] [Abstract][Full Text] [Related]
74. Cost Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines.
Ramos IC; Versteegh MM; de Boer RA; Koenders JMA; Linssen GCM; Meeder JG; Rutten-van Mölken MPMH
Value Health; 2017 Dec; 20(10):1260-1269. PubMed ID: 29241885
[TBL] [Abstract][Full Text] [Related]
75. Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.
King JB; Shah RU; Bress AP; Nelson RE; Bellows BK
JACC Heart Fail; 2016 May; 4(5):392-402. PubMed ID: 27039128
[TBL] [Abstract][Full Text] [Related]
76. In-Hospital Initiation of Angiotensin Receptor-Neprilysin Inhibitors-The Time Is Now.
Srivastava PK; Fonarow GC
JAMA Cardiol; 2019 Mar; 4(3):195-196. PubMed ID: 30810709
[No Abstract] [Full Text] [Related]
77. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
Velazquez EJ; Morrow DA; DeVore AD; Duffy CI; Ambrosy AP; McCague K; Rocha R; Braunwald E;
N Engl J Med; 2019 Feb; 380(6):539-548. PubMed ID: 30415601
[TBL] [Abstract][Full Text] [Related]
78. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.
DeVore AD; Braunwald E; Morrow DA; Duffy CI; Ambrosy AP; Chakraborty H; McCague K; Rocha R; Velazquez EJ;
JAMA Cardiol; 2020 Feb; 5(2):202-207. PubMed ID: 31825471
[TBL] [Abstract][Full Text] [Related]
79. Neprilysin inhibition: A brief review of past pharmacological strategies for heart failure treatment and future directions.
Howell EH; Cameron SJ
Cardiol J; 2016; 23(6):591-598. PubMed ID: 27665860
[TBL] [Abstract][Full Text] [Related]
80. ▼ Sacubitril valsartan for heart failure.
Drug Ther Bull; 2016 Jun; 54(6):66-9. PubMed ID: 27284124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
